Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
Mary Kathryn Abel, Michelle Melisko, Hope S. Rugo, A. Jo Chien, Italia Diaz, Julia K. Levine, A. Clark Griffin, Joseph McGuire, Laura J. Esserman, Hala T. Borno, Rita A. Mukhtar
Abstract
Enrollment in metastatic breast cancer trials usually requires measurable lesions, but patients with invasive lobular carcinoma (ILC) tend to form diffuse disease. We found that the proportion of patients with metastatic ILC enrolled in clinical trials at our institution was significantly lower than that of patients with invasive ductal carcinoma (IDC). Possible links between requiring measurable disease and decreased enrollment of ILC patients require further study to ensure equitable trial access.
Topics & Concepts
MedicineInvasive lobular carcinomaClinical trialOncologyInternal medicineBreast cancerDiseaseCancerCarcinomaRadiologyInvasive ductal carcinomaCancer Genomics and DiagnosticsGenetic factors in colorectal cancerEconomic and Financial Impacts of Cancer